Interleukin-6 and silent cerebral infarction in hemodialysis patients: a cross-sectional study

Eur J Neurol. 2011 Apr;18(4):625-30. doi: 10.1111/j.1468-1331.2010.03226.x. Epub 2010 Oct 6.

Abstract

Background: In patients with chronic renal failure undergoing hemodialysis (HD), silent cerebral infarctions (SCI) are associated with high mortality. Levels of interleukin-6 (IL-6) increase with renal dysfunction and may be a novel predictor for cerebrovascular events. We tested the hypothesis that increased IL-6 levels correlate with the occurrence of SCI in HD patients.

Methods: Using cranial magnetic resonance imaging findings, we divided 50 Japanese patients undergoing HD into two groups: with SCI (60 ± 7 years, mean ± SD, n = 27) and without SCI (60 ± 6 years, n = 23). We compared the gender, body mass index, metabolic profiles, IL-6 levels, and smoking habits between the two groups.

Results: We made the following observations: (i) The prevalence of diabetes or hypertension did not differ between the two groups, (ii) the level of IL-6 was higher in the with-SCI group than in the without-SCI group (P < 0.0001), (iii) the proportion of smokers was higher in the with-SCI group (P < 0.05), (iv) plasma level of high-density lipoprotein cholesterol was lower, whilst uric acid level was higher, in the with-SCI group (P < 0.05 and P < 0.05, respectively), and (v) multiple logistic regression analysis identified IL-6 levels as being significantly associated with the presence of SCI (odds ratio 3.13, 95% CI = 1.42-7.89, P < 0.0001).

Conclusions: This study indicates that patients with chronic renal failure who are maintained on HD exhibit an increased prevalence of SCI and that IL-6 is significantly associated with the presence of SCI in HD patients.

MeSH terms

  • Biomarkers / analysis
  • Cerebral Infarction / blood*
  • Cerebral Infarction / etiology
  • Cross-Sectional Studies
  • Female
  • Humans
  • Interleukin-6 / blood*
  • Kidney Failure, Chronic / therapy
  • Magnetic Resonance Imaging
  • Male
  • Middle Aged
  • Prognosis
  • Renal Dialysis / adverse effects*

Substances

  • Biomarkers
  • Interleukin-6